MedTrace Logo

Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

NCT01181674 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2020-05-21

Study results available
· View outcomes & findings →

Summary

The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.

Conditions

Interventions

DRUG

insulin glargine

sc injection

DRUG

metformin

oral administration

DRUG

acarbose

oral administration

BEHAVIORAL

lifestyle therapy

diet and exercise

DRUG

insulin glargine

sc injection

DRUG

metformin

oral administration

DRUG

acarbose

oral administration

BEHAVIORAL

lifestyle therapy

diet and exercise

OTHER

Standard glycemic care

as informed by the current clinical practice guidelines

Sponsors & Collaborators

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Hertzel Gerstein, MD · Population Health Research Institute

  • Natalia McInnes (nee Yakubovich), MD · Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-02-28
Completion
2015-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01181674 on ClinicalTrials.gov